Greensboro, NC, United States of America

Anatoly A Mazurov

This inventor holds 26 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Nicotinic Receptor Research. Top assignees: Targacept, Inc., Attenua, Inc., Other. Active years: 2005-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anatoly A Mazurov. Retrieved from https://idiyas.com/inventor/anatoly-a-mazurov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 16)

% Patents Active = 30.8

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 4.0

ph-index = 9

Forward Citations = 156(Granted Patents)

Location History:

Greenboro, NC (US) (2010)
Greensboro, NC (US) (2005 - 2017)

Company Filing History:

2 out of 834,513

Other

patents

Years Active: 2005-2017

Loading Chart...

Areas of Expertise:

Nicotinic Acetylcholine Receptor

Azabicycloalkanes

Therapeutic Applications

Pharmaceutical Compositions

Pain Relief

Central Nervous System

Selective Amides

Heteroaryl-Substituted

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9580434 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes (2017-02-28),

2. 9173876 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide (2015-11-03),

3. 8921410 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes (2014-12-30),

4. 8901151 - Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2014-12-02),

5. 8859609 - Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes (2014-10-14),

6. 8846715 - (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof (2014-09-30),

7. 8541447 - 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof (2013-09-24),

8. 8541446 - (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof (2013-09-24),

9. 8476296 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2013-07-02),

10. 8268860 - Sub-type selective amides of diazabicycloalkanes (2012-09-18),

11. 8198296 - Sub-type selective azabicycloalkane derivatives (2012-06-12),

12. 8158649 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-04-17),

13. 8143272 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-03-27),

14. 8124620 - 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-02-28),

15. 8124619 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof (2012-02-28),

Title: The Innovations of Anatoly A. Mazurov

Introduction

Anatoly A. Mazurov, located in Greensboro, NC, has made significant contributions to the field of pharmaceutical sciences. With a total of 26 patents, he has been at the forefront of innovations targeting neurons and neurotransmitter systems, particularly in the realm of central nervous system (CNS) disorders.

Latest Patents

Mazurov's latest inventions focus on nicotinic acetylcholine receptor subtype selective amides of diazabicycloalkanes. These compounds demonstrate an ability to selectively bind to neuronal nicotinic receptors of the α4β2 subtype within the CNS. The disclosed compounds and pharmaceutical compositions can be utilized to treat a variety of CNS disorders. Notably, these compounds alter the quantity of nicotinic cholinergic receptors in the brain, exhibit neuroprotective properties, and do so with minimal adverse effects, such as significant increases in blood pressure or gastrointestinal distress.

Another noted patent involves the preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide. This invention highlights compounds that can modulate the activity of neuronal nicotinic acetylcholine receptors. The processes for preparing these compounds and their pharmaceutical compositions further emphasize their potential in treating various CNS dysfunctions.

Career Highlights

Throughout his career, Anatoly A. Mazurov has been associated with Targacept, Inc., a company recognized for its innovative approaches in drug development focused on CNS disorders. His tenure there has reinforced his position as a reputable inventor and innovator in his field.

Collaborations

Mazurov has collaborated with notable professionals such as Lan Miao and Teresa Phillips, contributing to a dynamic research environment that fosters advancements in pharmacology and therapeutic applications. These partnerships have been instrumental in the successful development and patenting of his inventions.

Conclusion

Anatoly A. Mazurov continues to pave the way for breakthroughs in pharmacological treatments for CNS disorders through his inventive contributions. His expertise and dedication in the field have resulted in a substantial portfolio of patents that hold promise for enhancing medical treatments and improving patient outcomes.

Profile summary based on public USPTO records.